4//SEC Filing
Jenne Kyle 4
Accession 0001209191-20-054616
CIK 0001662524other
Filed
Oct 12, 8:00 PM ET
Accepted
Oct 13, 3:59 PM ET
Size
17.9 KB
Accession
0001209191-20-054616
Insider Transaction Report
Form 4
Jenne Kyle
Chief Commercial Officer
Transactions
- Disposition from Tender
Common Stock
2020-10-12$18.15/sh−52,012$944,018→ 0 total - Disposition to Issuer
Stock Option (right to buy)
2020-10-12$5.94/sh−32,751$194,541→ 0 totalExercise: $12.21Exp: 2027-06-04→ Common Stock (32,751 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-12$5.94/sh−143,374$851,642→ 0 totalExercise: $12.21Exp: 2027-06-04→ Common Stock (143,374 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-12$0.77/sh−299$230→ 0 totalExercise: $17.38Exp: 2028-01-01→ Common Stock (299 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-12$5.39/sh−34,200$184,338→ 0 totalExercise: $12.76Exp: 2030-03-18→ Common Stock (34,200 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-10-12$0.77/sh−13,701$10,550→ 0 totalExercise: $17.38Exp: 2028-01-01→ Common Stock (13,701 underlying)
Footnotes (5)
- [F1]This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $851,641.56, representing the difference between the exercise price of the option and the acquisition price of $18.15.
- [F2]This option, which provided that 1/4th of the shares would vest one year after May 15, 2017 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $194,540.94, representing the difference between the exercise price of the option and the acquisition price of $18.15.
- [F3]This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $230.23, representing the difference between the exercise price of the option and the acquisition price of $18.15.
- [F4]This option, which provided that 1/4th of the shares would vest one year after January 2, 2018 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $10,549.77, representing the difference between the exercise price of the option and the acquisition price of $18.15.
- [F5]This option, which provided that 1/4th of the shares would vest one year after March 19, 2020 and 1/48th of the shares would vest monthly thereafter over the next three years, was cancelled in connection with the merger of the Issuer with a wholly owned subsidiary of Ionis Pharmaceuticals, Inc. in exchange for a cash payment of $184,338.00, representing the difference between the exercise price of the option and the acquisition price of $18.15.
Documents
Issuer
AKCEA THERAPEUTICS, INC.
CIK 0001662524
Entity typeother
Related Parties
1- filerCIK 0001791857
Filing Metadata
- Form type
- 4
- Filed
- Oct 12, 8:00 PM ET
- Accepted
- Oct 13, 3:59 PM ET
- Size
- 17.9 KB